All Stories
The Series B Pipeline Looks Refreshingly Diversified
Before pulling data, one usually has a preconceived idea of what the results will show. In this case, looking at recent U.S. Series B investments, my assumption was that big rounds would be dominated by a few buzzy AI sectors. The reality, however, looks far more diversified. Startups securing the largest rounds run the gamut from biotech to robotics to security and more. Obviously AI is the leading theme, but the pipeline of funded companies is anything but cookie-cutter. Overall funding levels also look fairly healthy, with annual Series B funding moving steadily higher after hitting a low in 2023. This year is off to a strong start as well, as charted below. Round counts are also holding up at a steady level, an encouraging indicator for those worried about capital concentration thinning the ranks of funded companies. It may be happening at late stage, but Series B is not so dramatically affected. Investor favorites Even so, a good chunk of Series B investment did go to a handful of favored startups. Looking at rounds from the past six months, the largest was a $2 billion Nvidia-led financing for Reflection AI, a developer of open foundation models founded in 2024 by former Google DeepMind researchers. Another standout was Kailera Therapeutics, which is developing oral treatments for obesity. The then year-old company raised $600 million in October. Physical Intelligence, an AI robotics startup, also raised $600 million in a November Series B led by Google’s CapitalG. For a bigger-picture view, we used Crunchbase data to put together a list of 10 of the largest Series B recipients of the past six months. Round sizes grow bigger Another trend we’re seeing is that average round sizes are getting larger. So far in 2026, for instance, the average Series B is $68 million, which appears to be the highest on record. As you can see charted below, the average size of a Series B round has been inching higher for a few years. It’s not as pronounced as what we’re seeing at later-stage, which continues to set fresh records for deal size. But still, investors are putting more capital into their largest deals. Meanwhile, smaller Series B rounds are scarcer. From 2020 through 2023, for instance, there were typically about 150 rounds of between $1 million and $10 million each year. Last year, there were only 44 such rounds. Still plenty of variety While Series B investors may be consolidating their bets somewhat, they’re doing so across a wide range of sectors and technologies. Per Crunchbase data, more than a quarter of Series B funding over the past six months has gone to healthcare and biotech startups. About 15% has gone to robotics and hardware-related investments. Roughly half of Series B investment for the past six months also went to companies in AI-related categories across multiple industries. In addition, a majority of investment went to software-focused companies. At this stage and typical size, one can assume investors are no longer making risky bets on unproven upstarts. To get to Series B requires some impressive technological edge, early traction, or both. And for most, they’re just getting started. Related Crunchbase queries and lists: Related reading: Illustration: Dom Guzman
The Week’s 10 Biggest Funding Rounds: Space Tech, AI Infrastructure Lead Fundraises
Want to keep track of the largest startup funding deals in 2025 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a weekly feature that runs down the week’s top 10 announced funding rounds in the U.S. Check out last week’s biggest funding deal roundup here. The first week of March was a relatively brisk period for large startup funding rounds, led by three deals of $500 million or more in the space tech and AI infrastructure sectors. In addition, we saw some good-sized deals around healthcare, neuroscience and enterprise software. 1. Sierra Space, $550M, space tech: Sierra Space, a space and defense tech company that designs and manufactures satellites, spacecraft and space subsystems, secured $550 million in equity funding led by LuminArx Capital Management. The financing sets an $8 billion valuation for the 5-year-old, Louisville, Colorado-based company. 2. (tied) Ayar Labs, $500M, AI infrastructure: Ayar Labs, a producer of co-packaged optics for use in AI infrastructure, landed $500 million in Series E funding led by Neuberger Berman. The financing sets a $3.75 billion valuation for the 11-year-old, San Jose, California-based company. 2. (tied) Vast, $500M, space tech: Long Beach, California-based Vast, a startup developing next-generation space stations, announced it has raised $500 million in fresh funding. The financing includes $300 million in Series A equity and $200 million in debt, with Balerion Space Ventures as lead investor. 4. Findhelp, $250M, care platform: Findhelp, developer of a platform to coordinate care across health systems, governments, benefits providers and other entities, secured $250 million in investment from TPG’s The Rise Fund. Founded in 2010, Austin-based Findhelp describes its mission as connecting people to help and support systems. 5. Science Corp., $230M, neurotech: Alameda, California-based Science Corp., a biotech startup focused on brain-computer interface technologies, announced it has closed on a $230 million Series C fundraise. Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT and Quiet Capital were among the investors participating in the syndicated round. 6. Cart.com, $180M, e-commerce: Cart.com, provider of an e-commerce platform and logistics services for brands to sell across digital channels, picked up $180 million in growth equity investment. Springcoast Partners led the financing for the Houston-based company. 7. Grow Therapy, $150M, mental health care: Grow Therapy, a New York-based platform for providing mental health care, raised $150 million in Series D funding led by TCV and Goldman Sachs Growth Equity. 8. Cognito Therapeutics, $105M, neuroscience: Cambridge, Massachusetts-based Cognito Therapeutics, a developer of therapies for neurodegenerative diseases, secured $105 million in Series C funding. Morningside, IAG Capital Partners and Starbloom Capital led the financing. 9. Nominal, $80M, engineering software: Nominal, a self-described provider of tools for engineers to test and operate critical technology, picked up $80 million in new funding. Founders Fund led the financing, which set a $1 billion valuation for the Austin-based company. 10. Sage, $65M, health software: New York-based Sage, provider of a software platform for senior living and skilled nursing, raised $65 million in Series C funding led by Goldman Sachs Alternatives. Methodology We tracked the largest announced rounds in the Crunchbase database that were raised by U.S.-based companies for the period of Feb. 28-March 6. Although most announced rounds are represented in the database, there could be a small time lag as some rounds are reported late in the week. Illustration: Dom Guzman
Tim Draper On The AI Boom, Bitcoin’s Future And Building ‘Human Accelerators’
Few venture capitalists have the name recognition — or tenure — of Tim Draper. A fixture in Silicon Valley for decades, Draper has built a reputation for bold, often contrarian bets that have yielded some of the industry’s most notable wins, including early investments in SpaceX, Tesla, Coinbase, Skype and Twitch. His career, which spans his time as founder of Draper Associates, DFJ and the Draper Venture Network, has also included high-profile missteps — most notably Theranos — underscoring the risk and volatility that goes along with making bold wagers. A frequent personality on TV and social media, Draper is also known as a relentless champion for decentralized technology and a leading voice for bitcoin and blockchain. In 2024, he launched Draper TV, a media network, where he continues to host a global pitch competition called “Meet the Drapers.” The series, which is now entering its ninth season, invites viewers at home to invest alongside him in innovative startups. Draper exudes an almost schoolboy-like enthusiasm and passion when it comes to startups, technology, bitcoin and innovation. I recently spoke with him — while he was sporting his favorite purple and gold bitcoin tie — to get his thoughts on everything from his use of digital twins, how the current AI boom compares to previous cycles, and how he wishes policymakers approached tech regulation. This interview has been edited for clarity and brevity. Crunchbase News: What have you been up to lately? What’s occupying your time? Tim Draper, founder of Draper Associates. (Courtesy photo) Draper: We are doing something interesting with America 250 — we’re joining them for something called America’s Startup. We’re going to do a business plan competition around the country for college students. It kind of dovetails into “Meet the Drapers.” TikTok is one of our sponsors, so we’re thinking about doing shows in “small bites” for them. We’re also doing a lot with YouTube. This is the year we turn our distribution global. We had a reach of 300 million people, with 10 million seeing each episode, but we’re focusing on building the YouTube audience now because you get more control and understand the audience better. Then there is Draper University. We’re building relationships with various countries that send their top students or potential entrepreneurs to us. People call it a “pre-accelerator,” but I call it a “human accelerator.” We accelerate the people — they have to accelerate their own business. We take them through very difficult challenges: a three-day hackathon and survival training with the Navy SEALs, special forces and the US Army. Then they have a two-minute presentation to VCs. You’re using “digital twins.” How are you actually deploying AI in your daily operations? Yes, they are helping. They answer questions from entrepreneurs. On our site, they can talk with me or my digital twin, or they can send in a deck. My team has built these in a few different ways. One is a hologram by Proto at Draper University. On our website, we have a twin created by Randy Adams that can talk to entrepreneurs. We even have an AI — built by an intern — that evaluates pitch decks and “spits out” feedback. Beyond that, we use a tool called Seer that uses video to detect facial expressions; it can determine if an entrepreneur is passionate, lying or genuinely interesting. We’re also using a voice analysis tool — similar to how Coca-Cola reportedly hires people based on specific “voice models” that match their desired personality types — to identify the “entrepreneurial voice.” What do you think feels fundamentally different about the cycle that we’re in right now compared to previous ones? Weirdly, I don’t see a big difference. It’s as big as the dot-com boom, maybe bigger. I call it the Draper iS curve. Every industry goes through this. There is a little “i” — that’s the hype. It comes to a point (the dot on the i), and then it comes down because people are disenchanted. It sits there while engineers are hard at work, and then it grows into a big “S” that goes way bigger than the top of the i. It happened with the internet: 1999 was the climb, 2000 was the top, and 2001 was the crash. From 2001 to 2008, it grew into a huge boom. It’s happening with bitcoin now. And AI is right at the “dot” on the i or coming down off it. People are disenchanted because of energy issues, but it will eventually be bigger than anyone imagined, especially in robotics. What’s the trend that you think right now might be a little bit overhyped? And what’s something that’s underestimated? The quick answer is AI is overhyped, but I don’t believe that. Under-noticed is that Big Pharma would have you believe chemotherapies are the most important thing — that you create a molecule and use it forever, and then need another molecule for the side effects. We’re moving from chemotherapies to bio-cures: stem cells, cloning and genetic engineering. Also, companies we used to call “space and transportation” are now called dual-use. The Space Force and governments are buying in because they realize they are way behind the commercial sector. And bitcoin is in that period where “nobody cares,” but it’s slowly taking over. Do you see bitcoin actually replacing the dollar for daily use? For now, nobody wants to spend it because they think it will be worth more. But eventually, retailers will say, “We only take bitcoin.” If that happens, there will be a run on the dollar. People worry about quantum computing hacking bitcoin, but they’ll hack the banks first — it’s way easier. I’d be more concerned about money in a bank than on a bitcoin ledger. Bitcoin also keeps perfect records; we wouldn’t need 85,000 IRS agents because the blockchain can just pay whoever needs to be paid. Where do you think the biggest potential for returns in the AI space are? Tooling, vertical AI, AI-native companies? One or two general AI companies will win big and become “hungry giants,” the way Microsoft was for software or bitcoin is for tech applications. A lot of people working around the edges might just be acquired by the AGI. We’ve funded companies doing vertical AI: AI for patents, AI for science. But remember, the big winners at the start of the internet were AOL, Yahoo and Netscape, and none of them ended up being a big part of the internet later. We don’t know who will rise from the ashes yet. If you could implement one policy to accelerate innovation, what would that policy be? Don’t regulate in anticipation of fearful outcomes. Regulate after something bad happens. Otherwise, you put a dark cloud over every innovator. I would also sunset laws. The ’33 and ’40 Acts are just keeping the poor poor and the rich rich. We should create a free market in education, too — let the best schools thrive and the worst die. Some would argue in the case of bitcoin, we were slow to regulate. Do you disagree? The U.S. just decided everything was a security and made it illegal. That’s why innovators are geofencing the U.S. to protect themselves from the SEC‘s long arms. Countries like El Salvador, Japan, Dubai and Abu Dhabi are rocking because they say “do it.” I say decentralize everything. The guy at the tiller of the ship knows better than the general in Washington, D.C. You don’t want a president telling you how to raise your kids; you’ll do a better job than they will. What’s the trait you now prioritize in founders that you didn’t a decade ago? A love for the customer. It has to be an obsession. That love becomes a viral effect; customers love the product so much they tell everyone. People will naturally follow a leader who is that obsessed with their customer. Illustration: Dom Guzman
Science Corp., Another Braintech Startup Founded By Neuralink Alums, Raises $230M Series C
Science Corp., a biotech startup focused on brain-computer interface technologies, announced Thursday that it has closed on a $230 million Series C fundraise. Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT and Quiet Capital were among the investors participating in the syndicated round. With the latest financing, Science Corp. says it has now raised $489 million since its 2021 inception. The Alameda, California-based company’s most recent raise previously was a $104 million convertible note led by Khosla last April. While Science did not disclose its valuation in the announcement, it has been reported that the company is now valued at $1.5 billion. The Neuralink competitor is working on both a brain-implant system and a retina implant to treat eye diseases. Notably, it was founded by Max Hodak, a co-founder of Neuralink, and Alan Mardinly, formerly part of Neuralink’s leadership team. Science says it acquired MEMS, or microelectromechanical systems, facility assets in North Carolina, giving it the ability to manufacture in-house chip/MEMS for neural interface devices. Many competitors outsource manufacturing, which the company noted can slow down iteration or increase cost and risk. The company says the funding will accelerate the commercialization of its PRIMA BCI retinal implant, with the expansion of its PRIMA clinical trial program to include other retinal diseases such as Stargardt disease and retinitis pigmentosa. Big deals for neural interface startups Billions of venture dollars have flowed into the neural interface and brain technology space in recent years, with Neuralink being the most well-funded of the group. Last June, the Elon Musk-founded brain implant startup, announced a $650 million Series E funding round. Other companies working on computer-brain interfaces have also raised significant venture backing, a review of Crunchbase data shows. Another example is China’s Stairway Medical, a Neuralink competitor that raised a $48 million Series B funding round in February 2025, reportedly the largest-ever funding round for a startup in the field in that country. It also raised an unknown amount of capital in December. It’s unclear how much the company raised in previous venture rounds. Meanwhile, yet another Neuralink competitor, Austin-based Paradromics, announced last June that it had performed its first human surgery using its Connexus Brain-Computer Interface. Paradromics has raised a total of $108.6 million in funding since its 2015 inception, according to Crunchbase data. Investors include Fusion Fund, FJ Labs, 15th Rock, Alpha Edison and DARPA. Related Crunchbase query: Related Reading: Illustration: Dom Guzman
Exclusive: Founded By 2 Brothers In Their 20s, YC-Backed Denki Raises $4.1M To Automate Financial Audits
Denki, which has built AI-powered software for financial auditors at public companies, has raised $4.1 million in funding, the startup tells Crunchbase News exclusively. Founded in 2025 by brothers Felipe Jin Li (24) and David Jin Li (20), San Francisco-based Denki aims to build “modern” infrastructure for financial audits, which verify that financial statements are accurate and controls are functioning. The startup wants to help replace manual, “evidence-heavy” processes with software automation that makes audits run more like code. David Jin Li and Felipe Jin Li, co-founders of Denki. (Courtesy photo) “Denki helps auditors review and prepare evidence more quickly, document their work more effectively, and test process controls more rigorously,” CEO Felipe told Crunchbase News. “With higher risk coverage and reduced costs, public companies can comply better with financial regulations.” Base10 Partners and Shine Capital co-led the raise, which included participation from Y Combinator, 20VC and others. Denki also participated in YC’s Fall 2025 cohort. The raise comes amid a broader surge in funding to fintech startups, particularly those that apply AI in their offerings. Global funding to VC-backed financial technology startups totaled $52.9 billion in 2025, per Crunchbase data. That’s a 27% increase from 2024’s total of $41.6 billion raised. Interestingly, the most-active investor in the space by far all year, in terms of deal volume, was Denki backer Y Combinator, which participated in 151 fintech startup deals last year. That’s up 24.8% compared to the 121 deals it wrote checks into in 2024. Landing on capital and an idea The two brothers grew up in Spain and the U.K. Upon moving to London to study computer science, the pair participated in hackathons organized by Meta, OpenAI, ElevenLabs and VC-sponsored programs, and won several competitions. “That opened up opportunities, including being offered a $135,000 pre-seed check before we had an idea, which we declined,” Felipe recalls. The brothers eventually accepted a small angel check from a former staff research scientist at DeepMind, which gave them a few months of runway to explore ideas before being accepted into the Y Combinator Fall 2025 batch. “We spent time digging into compliance and landed on audit. It is a technically rich problem, with large volumes of unstructured data, high regulatory stakes and very little modernization in tooling,” Felipe said. “It also connected naturally to what we had each been doing.” David was building financial data pipelines at Macro Hive — a company trusted by top hedge funds — turning messy data into usable information. Felipe was working on his Ph.D. in explainable AI at University College London, evaluating vision-language models and making black-box systems “interpretable.” They discovered that a common approach to addressing all the manual work required by auditors was to build Excel extensions designed to make audit work faster. “We believe it is worth changing the status quo by moving away from Excel as the primary workspace,” Felipe said. Denki, he said, offers cleaner logs and less room for sample manipulation. Also, because the brothers have a research background, they are “constantly” staying on top of new concerns. “One major audit risk today is AI fraud,” said Felipe. “There is promising research on detecting forged AI-generated receipts using invisible watermarks, and translating that research into something auditors can actually use is a big part of what we do.” Denki makes money by offering a tiered SaaS annual contract that depends on the number of controls automated, team size and other integration factors. Its customers are pre-IPO and publicly traded companies. Building for a ‘high-stress industry’ under scrutiny Denki’s founders believe their solution is timely. Last year, the Public Company Accounting Oversight Board imposed the third-highest cumulative penalties in its 21-year enforcement history, totaling $17.7 million, according to a Thomson Reuters report. That was after issuing a record $35.7 million in penalties in 2024. The Jin Li brothers believe those metrics signal that “scrutiny is intensifying even as traditional methods strain under complexity.” For now, Denki is a two-person company, but it plans to hire engineers and auditors with its new capital. Ade Ajao, Base10 Partners co-founder and managing partner, told Crunchbase News that his firm was impressed by the brothers’ “passion for the industry” and their focus on automating “very discrete tasks” for auditors. “It was unusual to see such young people so strongly empathetic to issues in auditing but it was clear they were determined to build something great for this industry,” he wrote via email. “But also it’s a large market that is burdened with labor supply constraints (which is not getting any better), in a high-stress industry with ever increasing scrutiny.” Related Crunchbase query: Related reading: Illustration: Dom Guzman
Active Investors Spent More On Fewer Deals In February
More money, fewer deals. That’s the broad direction for active startup investors of late. They’re increasingly concentrating capital among generative AI heavy hitters and prominent unicorns, and making fewer small bets on unproven founders. February was perhaps the culmination of this trend. The month closed with the largest startup investment of all time — OpenAI’s $110 billion financing — but did not bring a jump in overall deal count, including by many active investors. Still, the top three most-active investors in terms of venture round count last month — Andreessen Horowitz, Y Combinator and Bessemer Venture Partners — managed to keep busy. And among lead investors, SoftBank, Nvidia and Amazon together collectively backed the biggest deal to date. Below, we look at active investors across multiple metrics, including active venture investors, lead backers and spendiest dealmakers. Active venture investors We’ll start with active investors participating in rounds of $5 million and up. By this metric, Y Combinator came out on top, partaking in 15 reported rounds. The incubator commonly takes small stakes in follow-on financings for companies it helped launch. Andreessen Horowitz was a close second, with 14 deals, followed by Bessemer Venture Partners, with 12. Active lead investors Andreessen Horowitz was far in the lead among the most-active lead investors in rounds over $5 million, with nine reported deals. Next in the ranks were Bessemer Ventures, with five lead deals, followed by Index Ventures, RA Capital Management and Accel, with four each. Below, we rank the 14 most-active lead investors for the month. Highest-spending lead investors The most-active dealmakers, however, were generally not the ones writing the largest checks. To get a sense of who put the most capital to work in February, we looked at lead investors in the most valuable rounds.1 Among lead investors, SoftBank, Nvidia and Amazon, which backed OpenAI’s $110 billion round, were by far the spendiest. Next up was Dragoneer Investment Group, which co-led Anthropic’s $30 billion Series G and Waymo’s $16 billion Series D. After that came the other six firms that co-led the Anthropic financing. Below, we rank the 17 lead investors in the most-valuable funding rounds. Short month, big checks For such a short month, February certainly managed to squeeze in an outsized share of huge rounds, led by OpenAI, Anthropic and Waymo. Yet activity held up at other stages as well, with Y Combinator and others ensuring there’s still a plentiful pipeline of seed-funded companies to grow into the next industry giants. We’ll stay tuned to see if March brings more of the same. Related Crunchbase query: Related reading: Illustration: Dom Guzman
Intersection Of Biosecurity And AI Sees Seed-Stage Spike
There are plenty of things to worry about these days, and the ability of AI to weaponize biology into one of the largest threats facing our world isn’t top of mind for most of us. Seed-stage investors have a different view. Over the past few months, two startups focused on the intersection of AI and biosecurity have raised good-sized initial rounds with OpenAI among their investors. Valthos, a developer of AI systems that identify biological threats and design countermeasures, raised $30 million last fall in its first known funding round. The New York-headquartered company counts Founders Fund and Lux Capital as backers, along with OpenAI. Weeks later, Red Queen Bio, a self-described AI biosecurity company, secured $15 million in a seed round led by OpenAI and joined by investors including Cerberus Ventures, Fifty Years and Halcyon Futures. The company’s operating thesis is that as AI capabilities advance, biological risks grow exponentially, so defenses must scale at the same rate. On the nonprofit front, meanwhile, Cambridge, Massachusetts-based SecureBio secured grant funding from multiple sources last year, including $1.4 million from Coefficient Giving in December. The organization’s stated mission is to secure the future from catastrophic pandemics. A drop in the AI bucket Given all the capital that has poured into artificial intelligence of late, these are not comparatively large sums going to biosecurity. To put it in perspective, the two biggest seed rounds are less than one-tenth of a percent of the record-setting $110 billion financing OpenAI secured last week. What’s more noteworthy than sums invested is these are relatively new areas for startups to scale. Per Crunchbase data, the term “biosecurity” and similar terminology has cropped up in funded startup descriptions but not so much in the context of AI. Funded startups around this theme have also commonly focused on livestock. The Australian startup ExoFlare, for instance, raised a few million two years ago, per Crunchbase data, with a focus on tracking biosecurity risks for cattle, pigs, eggs and poultry. And Nebraska-based Daro picked up $1.1 million last year for a business focused on swine disease surveillance. Running in place In addition to their AI focus, the latest crop of biosecurity seed-funded startups stand out for the dire scenarios they’re hoping to contain. Per Valthos, it’s now faster to weaponize biology than to advance new cures, an ominous development that AI leaders have identified as one of the largest threats of our time. The company envisions a future where any threat to human health can be immediately identified and neutralized. Red Queen Bio evokes a similarly alarming specter of threats, reflected in its nomenclature. The Red Queen hypothesis, a notion that evolution requires constant adaptation to ever-evolving threats, stems from a “Through the Looking Glass” passage. In it, the tyrannical Red Queen explains that in her kingdom, “it takes all the running you can do, to keep in the same place.” Running to keep in the same place seems a more broadly apt metaphor for the modern era in myriad domains, not just biosecurity. However, this is one of the spaces where not keeping up carries the potentially deadliest penalties. Illustration: Dom Guzman
Eight Sleep Raises $50M At $1.5B Valuation To Expand Into ‘Predictive, AI-Driven Health’
Eight Sleep, a startup developing sleep technology products, announced Wednesday that it has raised $50 million at a $1.5 billion valuation. Tether Investments led the “strategic” investment in the New York-based startup, which has now raised more than $250 million in total funding. Eight Sleep raised $100 million last August, so this financing marks its second round in a year’s time. At the time of that raise, the company was valued at $1 billion, up from its approximately $500 million valuation at the time of its $86 million Series C round in August 2021. Eight sleep co-founders: Massimo Andreasi Bassi, Matteo Franceschetti and Alex Zatarain. (Courtesy photo) Founded in 2014, Eight Sleep describes itself as a “sleep technology” company that combines technology, physiology and data “to unlock deeper sleep and better health.” The company started out selling a smart mattress, or Pod, that uses embedded sensors to collect data to study trends about how people sleep. One could say the company was ahead of its time — in 2018, it launched an AI-powered sleep coach that tells users things like: “Last night, you slept 40 minutes less than your average this month” or “This week, your REM sleep is lower than average. Try going to bed 30 minutes earlier tonight.” The new capital will fund its expansion from sleep optimization into “predictive, AI-driven health,” it said. Executives described 2025 as a “milestone” year in which Eight Sleep achieved free cash flow positivity and launched three new products: Pod 5, Pod Pillow Cover and Thermal Blanket. “Sleep was just the beginning,” said Matteo Franceschetti, co-founder and CEO of Eight Sleep, in a release. “We’ve built the most advanced AI-powered health sensing system in the world — one that learns your body better every night and acts on that knowledge. This investment gives us the resources to take that intelligence beyond the bedroom and into every dimension of personal health. … Our goal is to build the defining health technology company of this generation.” Eight Sleep is not the only sleep-focused company to raise capital lately. Over the past few years, investors have poured hundreds of millions into an array of companies working on treatments for sleep-related ailments and technology to help improve sleep quality. Oura, maker of the popular wearable rings that record and analyze biometric data, is the largest investment recipient in this area. It’s raised $1.25 billion in equity funding to date, including a $900 million Series E at an $11 billion valuation in October 2025. Related Crunchbase query: Related reading: Illustration: Dom Guzman